Candriam S.C.A. Assembly Biosciences, Inc. Transaction History

Candriam S.C.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$1.46 - $2.45 $2.68 Million - $4.5 Million	-1,838,221 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$2.13 - $3.46 $786,768 - $1.28 Million	369,375 Added 25.15%	1,838,221 $4.28 Million
Q3 2021 Nov 09, 2021	BUY	$3.14 - $3.9 $1.11 Million - $1.38 Million	355,092 Added 31.88%	1,468,846 $5.11 Million
Q2 2021 Jul 20, 2021	SELL	$3.8 - $4.56 $86,605 - $103,926	-22,791 Reduced 2.01%	1,113,754 $4.32 Million
Q4 2020 Jan 22, 2021	BUY	$4.87 - $17.29 $3.34 Million - $11.9 Million	686,545 Added 152.57%	1,136,545 $6.88 Million
Q3 2020 Oct 19, 2020	BUY	$15.08 - $27.04 $6.79 Million - $12.2 Million	450,000 New	450,000 $7.4 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $737M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.